GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » American Cryostem Corp (OTCPK:CRYO) » Definitions » 3-Year RORE %

American Cryostem (American Cryostem) 3-Year RORE % : 0.00% (As of Jun. 2022)


View and export this data going back to 2010. Start your Free Trial

What is American Cryostem 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. American Cryostem's 3-Year RORE % for the quarter that ended in Jun. 2022 was 0.00%.

The industry rank for American Cryostem's 3-Year RORE % or its related term are showing as below:

CRYO's 3-Year RORE % is not ranked *
in the Biotechnology industry.
Industry Median: -6.69
* Ranked among companies with meaningful 3-Year RORE % only.

American Cryostem 3-Year RORE % Historical Data

The historical data trend for American Cryostem's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Cryostem 3-Year RORE % Chart

American Cryostem Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.26 -25.69 -14.47 -9.38 33.71

American Cryostem Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.89 33.71 41.11 55.24 57.94

Competitive Comparison of American Cryostem's 3-Year RORE %

For the Biotechnology subindustry, American Cryostem's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


American Cryostem's 3-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, American Cryostem's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where American Cryostem's 3-Year RORE % falls into.



American Cryostem 3-Year RORE % Calculation

American Cryostem's 3-Year RORE % for the quarter that ended in Jun. 2022 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.074--0.012 )/( -0.107-0 )
=-0.062/-0.107
=57.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2022 and 3-year before.


American Cryostem  (OTCPK:CRYO) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


American Cryostem 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of American Cryostem's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


American Cryostem (American Cryostem) Business Description

Traded in Other Exchanges
N/A
Address
1 Meridian Road, Suite 5, Eatontown, NJ, USA, 07724
American Cryostem Corp is a biotechnology company which standardizes adipose tissue-derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The company acts as an innovator of adipose tissue and stem cell platform technologies. It provides the clinical grade, adipose tissue and adult stem cell collection, processing, and cryo-preservation technology, providing first-in-class cellular therapy products and services for patients, physicians and researchers based on the transformative science of Regenerative and Personalized Medicine.
Executives
John S Arnone director, officer: Chairman 111 GREAT NECK RD, GREAT NECK NY 11021
Anthony Francis Dudzinski director, officer: COO 188 EAST BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Acs Global, Inc. 10 percent owner 188 E. BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Christopher Joseph Neill 10 percent owner 188 EAST BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Hector Medina director, 10 percent owner, officer: President and Director 1206 STAGECOACH TRAIL LOOP, CHULA VISTA CA 91915